News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Subscribe To Our Newsletter & Stay Updated
